Menu
Not yet recruiting NCT06894160

Safety and Usability of the EXPLORER Exoskeleton in Adults With Neuromuscular Diseases

No phase Interventional Neuromuscular Disorders

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Adults EXPLORER.
Who it may be relevant to
Registry conditions: Neuromuscular Disorders. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Spain
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Safety and Usability of Adults EXPLORER Exoskeleton in With Neuromuscular Diseases

Overview

Neurodevelopmental disorders frequently result in abnormal development of the Central Nervous System (CNS), often leading to motor impairments such as difficulty in standing and walking. EXPLORER is a robotic exoskeleton for gait rehabilitation, specifically designed for adults aged 18 to 85 with motor disabilities.The aim of this study is to evaluate the safety and usability of the EXPLORER for adults with motor disability.

Detailed description

Neurodevelopmental disorders frequently result in abnormal development of the Central Nervous System (CNS), often leading to motor impairments such as difficulty in standing and walking. EXPLORER is a robotic exoskeleton for gait rehabilitation, specifically designed for adults aged 18 to 85 with motor disabilities. The aim of this study is to evaluate the safety and usability of the EXPLORER for adults with motor disability.

This study will involve testing the gait-assistance exoskeleton in healthy patients during the first phase, and in patients with stroke (ACV), acquired brain injury (DCA), multiple sclerosis (EM), and muscular dystrophy (LM) during the second phase. The study will consist of two phases:

Phase 1: One visit with the device in healthy patients to assess the initial safety and comfort of the device.

Phase 2: A screening visit (S0) followed by two treatment visits with the device (V1-V2) in patients with ACV, DCA, EM, and LM to determine the effectiveness of the device in treating motor impairments caused by these conditions.

The goal of the study is to evaluate the safety and usability of the device in patients with ACV, DCA, EM, and LM, in order to identify potential benefits in improving gait, muscle strength, and overall functionality in this patient group.

Interventions

  • Device Adults EXPLORER
    Two sessions with the robotic gait device in patients with neuromuscular diseases.

Primary outcome measures

  • Serious Adverse Events [Time frame: Through study completion, an average of 1 month]
  • Falls prevalence [Time frame: Through study completion, an average of 1 month]
  • Heart Rate [Time frame: Through study completion, an average of 1 month]
  • Skin integrity [Time frame: Through study completion, an average of 1 month]
  • Device usage time [Time frame: Through study completion, an average of 1 month]
  • Level of Spasticity [Time frame: Through study completion, an average of 1 month]
  • Level of fatigue [Time frame: Through study completion, an average of 1 month]
  • Donning and doffing time [Time frame: Through study completion, an average of 1 month]
  • Level of assistance a participant requires for walking [Time frame: Through study completion, an average of 1 month]
  • Walking ability of individuals with spinal cord injuries [Time frame: Through study completion, an average of 1 month]

Eligibility criteria

Inclusion criteria related to the device characteristics:

  • Weight < 100 kg.
  • Hip width between 30 - 45 cm.
  • Distance from the hip joint center to the knee joint center: 36 cm - 50 cm.
  • Distance from the knee joint center to the floor: 43.5 cm - 59.5 cm.
  • Patients must be able to follow simple instructions.
  • MAS < 3 in lower limbs.
  • EU shoe size between 36 and 45.
  • Absence of pathology affecting movement (only valid for phase 1 of the current study).

Inclusion criteria related to the study:

  • Age 18-85 years.
  • Diagnosis of stroke (ACV), acquired brain injury (DCA), multiple sclerosis (EM), muscular dystrophy (LM), or cerebral palsy (PC).
  • Gait difficulty: those who require assistance to walk using technical aids, assistance, or supervision from others.
  • FAC score in participants with DCA, stroke, or MS < 4.
  • WISCI II score in participants with MD < 20.

Exclusion criteria

  • Spasticity (MAS) = 3 in lower limbs.
  • Skin alterations in the areas of contact with the device.
  • Planned surgical intervention during the study duration.
  • Two or more osteoporotic fractures in the lower limbs in the last 2 years.
  • Presence of other conditions that cause exercise intolerance (such as uncontrolled hypertension, coronary artery diseases, arrhythmia, congestive heart failure, severe lung disease).
  • Surgical operation in the 3 months prior to the start of the study on the limbs and/or spine.
  • Psychiatric disorders that interfere with proper use of the device or participation in the study, such as impulsivity or inability to understand simple instructions.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Spain · 1 center
  • Hospital Universitario La Paz — Madrid

Identifiers

NCT: NCT06894160 · EXP-A-US

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗